FDA Panel Recommends First Over-the-Counter Birth Control Pill Opill

A panel of independent medical experts for the FDA voted unanimously in favor of allowing the hormonal birth control pill Opill to be sold over the counter.
HRA Pharma conducted a clinical trial with roughly 900 participants who reported taking the pill, called Opill, correctly more than 90 percent of the time.
Advocates argue that over-the-counter birth control would benefit people of color and those living in rural, underserved communities who face barriers to accessing healthcare.
Major medical groups are backing the request, but some groups are opposed, citing safety concerns and potential harm to women's health.
Making the medication available over the counter should increase access and reduce unintended pregnancies.